In June 2010, Neurocrine Biosciences entered into an exclusive worldwide collaboration with AbbVie (formerly Abbott) to develop and commercialize elagolix for women’s health. Under the terms of the agreement, AbbVie is responsible for future development and commercialization.
In 2018, AbbVie received U.S. Food and Drug Administration approval for ORILISSA® (elagolix) to treat pain associated with endometriosis. In 2020, AbbVie received U.S. Food and Drug Administration approval for ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) to manage heavy menstrual bleeding associated with uterine fibroids in pre menopausal women. Under the collaboration, elagolix is also being investigated for the treatment of polycystic ovary syndrome. AbbVie is responsible for all development, marketing, and commercialization costs, and Neurocrine Biosciences is entitled to a royalty on worldwide sales of ORILISSA, ORIAHNN, and any other product containing elagolix.